{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-039770","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.754063+00:00","generated_at":"2026-06-15T00:53:03.938817+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CorMedix Q1 net loss $10.6M; DefenCath NDA resubmitted to FDA for 6-month review","bullets":["Q1 net loss $10.6M ($0.24/share) vs $7.0M loss in Q1 2022; operating expenses $11.0M, up 57% YoY due to pre-launch activities.","DefenCath NDA resubmitted to FDA; classified as Type 2 resubmission with 6-month review cycle, target action date November 2023.","CMS proposed rule grants DefenCath NTAP up to $17,111 per hospital stay, contingent on FDA approval by July 1, 2024.","US Patent Office issued notice of allowance for DefenCath composition, extending IP protection to 2042.","Cash and short-term investments $55.6M; management believes sufficient to fund operations through first half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-039770","json":"https://secwatch.observer/filing/0001213900-23-039770.json","markdown":"https://secwatch.observer/filing/0001213900-23-039770.md","text":"https://secwatch.observer/filing/0001213900-23-039770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023039770/0001213900-23-039770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023039770/ea178530-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:53:03.938817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3bee15635a7607e65b61cdaa03b695b25d7d9430","claim":"CorMedix Inc. reported first quarter ended March 31, 2023 results: net income net loss of $10.6 million, EPS $0.24 per share.","evidence_excerpt":"For the first quarter of 2023, CorMedix recorded a net loss of $10.6 million, or $0.24 per share, compared with a net loss of $7.0 million, or $0.18 per share, in the first quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390023039770/0001213900-23-039770-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"net loss of $10.6 million"},{"label":"EPS","value":"$0.24 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}